Comparison of clinical parameters and drug between patients treated with or without belimumab at baseline
| Factor . | Standard therapy . | Belimumab . | P value . |
|---|---|---|---|
| Number of patients | 112 | 112 | |
| Laboratory examination | |||
| Serum creatinine, umol/L | 64.50 [56.38, 79.19] | 66.50 [55.00, 89.50] | 0.694 |
| eGFR | 107.64 [82.94, 120.57] | 108.58 [79.63, 120.32] | 0.700 |
| ≥90 (%) | 80 (71.4) | 76 (67.9) | 0.663 |
| ≥60 (%) | 94 (83.9) | 88 (78.6) | 0.392 |
| Serum albumin, g/L | 38.83 [34.77, 41.42] | 32.50 [28.70, 36.54] | <0.001 |
| C3, g/L | 0.93 (0.23) | 0.91 (0.25) | 0.590 |
| C4, g/L | 0.16 [0.13, 0.23] | 0.18 [0.11, 0.25] | 0.681 |
| IgA, g/L | 2.59 [1.96, 3.25] | 2.32 [1.75, 3.08] | 0.147 |
| IgG, g/L | 10.95 [8.17, 13.70] | 10.60 [7.68, 12.98] | 0.467 |
| IgM, g/L | 0.70 [0.51, 1.07] | 0.68 [0.45, 1.06] | 0.404 |
| Lupus anticoagulant | 1.58 [1.11, 2.40] | 1.08 [0.76, 1.68] | <0.001 |
| Proteinuria, g/24h | 0.78 [0.26, 2.45] | 1.17 [0.41, 2.58] | 0.059 |
| Urine WBC, WBC/ul | 12.00 [6.22, 33.11] | 13.25 [6.00, 42.25] | 0.906 |
| Urine RBC, RBC/ul | 14.75 [5.00, 52.50] | 12.00 [4.25, 53.75] | 0.443 |
| Positive ANA | 111 (99.1) | 107 (95.5) | 0.212 |
| Positive anti-dsDNA | 65 (58.0) | 58 (51.8) | 0.421 |
| Positive anti-Sm | 26 (23.2) | 31 (27.7) | 0.540 |
| Positive anti-ssA | 63 (56.2) | 62 (55.4) | 1.000 |
| Positive anti-ssB | 13 (11.6) | 18 (16.1) | 0.439 |
| Pathology | |||
| ISN/RPS class | |||
| III | 3 (10.3) | 5 (10.4) | 1 |
| IV | 15 (51.7) | 11 (22.9) | 0.013 |
| III/IV+V | 11 (37.9) | 25 (52.1) | 0.249 |
| V | 0 (0.0) | 7 (14.6) | 0.041 |
| Crescent (%) | 13.33 [0.00, 28.57] | 5.50 [0.00, 14.56] | 0.126 |
| AI | 7.00 [4.00, 9.00] | 5.00 [2.00, 10.00] | 0.150 |
| CI | 2.00 [1.00, 5.00] | 2.00 [1.00, 4.00] | 0.923 |
| Therapy | |||
| ATM (%) | 75 (67.0) | 85 (75.9) | 0.183 |
| AZA (%) | 1 (0.9) | 1 (0.9) | 1.000 |
| CNI (%) | 16 (14.3) | 54 (48.2) | <0.001 |
| CTX (%) | 6 (5.4) | 13 (11.6) | 0.149 |
| LEF (%) | 10 (8.9) | 8 (7.1) | 0.807 |
| MMF (%) | 54 (48.2) | 51 (45.5) | 0.789 |
| RAASi (%) | 43 (38.4) | 57 (50.9) | 0.080 |
| Steroid (%) | 107 (95.5) | 108 (96.4) | 1.000 |
| Dosage of steroid, mg/day | 15.00 [10.00, 20.00] | 15.00 [7.50, 25.62] | 0.726 |
| Major treatment regimen | |||
| Steroid only (%) | 32 (28.6) | 11 (9.8) | <0.001 |
| Steroid + CTX (%) | 6 (5.4) | 13 (11.6) | 0.149 |
| Steroid + MMF (%) | 50 (44.6) | 45 (40.2) | 0.589 |
| Factor . | Standard therapy . | Belimumab . | P value . |
|---|---|---|---|
| Number of patients | 112 | 112 | |
| Laboratory examination | |||
| Serum creatinine, umol/L | 64.50 [56.38, 79.19] | 66.50 [55.00, 89.50] | 0.694 |
| eGFR | 107.64 [82.94, 120.57] | 108.58 [79.63, 120.32] | 0.700 |
| ≥90 (%) | 80 (71.4) | 76 (67.9) | 0.663 |
| ≥60 (%) | 94 (83.9) | 88 (78.6) | 0.392 |
| Serum albumin, g/L | 38.83 [34.77, 41.42] | 32.50 [28.70, 36.54] | <0.001 |
| C3, g/L | 0.93 (0.23) | 0.91 (0.25) | 0.590 |
| C4, g/L | 0.16 [0.13, 0.23] | 0.18 [0.11, 0.25] | 0.681 |
| IgA, g/L | 2.59 [1.96, 3.25] | 2.32 [1.75, 3.08] | 0.147 |
| IgG, g/L | 10.95 [8.17, 13.70] | 10.60 [7.68, 12.98] | 0.467 |
| IgM, g/L | 0.70 [0.51, 1.07] | 0.68 [0.45, 1.06] | 0.404 |
| Lupus anticoagulant | 1.58 [1.11, 2.40] | 1.08 [0.76, 1.68] | <0.001 |
| Proteinuria, g/24h | 0.78 [0.26, 2.45] | 1.17 [0.41, 2.58] | 0.059 |
| Urine WBC, WBC/ul | 12.00 [6.22, 33.11] | 13.25 [6.00, 42.25] | 0.906 |
| Urine RBC, RBC/ul | 14.75 [5.00, 52.50] | 12.00 [4.25, 53.75] | 0.443 |
| Positive ANA | 111 (99.1) | 107 (95.5) | 0.212 |
| Positive anti-dsDNA | 65 (58.0) | 58 (51.8) | 0.421 |
| Positive anti-Sm | 26 (23.2) | 31 (27.7) | 0.540 |
| Positive anti-ssA | 63 (56.2) | 62 (55.4) | 1.000 |
| Positive anti-ssB | 13 (11.6) | 18 (16.1) | 0.439 |
| Pathology | |||
| ISN/RPS class | |||
| III | 3 (10.3) | 5 (10.4) | 1 |
| IV | 15 (51.7) | 11 (22.9) | 0.013 |
| III/IV+V | 11 (37.9) | 25 (52.1) | 0.249 |
| V | 0 (0.0) | 7 (14.6) | 0.041 |
| Crescent (%) | 13.33 [0.00, 28.57] | 5.50 [0.00, 14.56] | 0.126 |
| AI | 7.00 [4.00, 9.00] | 5.00 [2.00, 10.00] | 0.150 |
| CI | 2.00 [1.00, 5.00] | 2.00 [1.00, 4.00] | 0.923 |
| Therapy | |||
| ATM (%) | 75 (67.0) | 85 (75.9) | 0.183 |
| AZA (%) | 1 (0.9) | 1 (0.9) | 1.000 |
| CNI (%) | 16 (14.3) | 54 (48.2) | <0.001 |
| CTX (%) | 6 (5.4) | 13 (11.6) | 0.149 |
| LEF (%) | 10 (8.9) | 8 (7.1) | 0.807 |
| MMF (%) | 54 (48.2) | 51 (45.5) | 0.789 |
| RAASi (%) | 43 (38.4) | 57 (50.9) | 0.080 |
| Steroid (%) | 107 (95.5) | 108 (96.4) | 1.000 |
| Dosage of steroid, mg/day | 15.00 [10.00, 20.00] | 15.00 [7.50, 25.62] | 0.726 |
| Major treatment regimen | |||
| Steroid only (%) | 32 (28.6) | 11 (9.8) | <0.001 |
| Steroid + CTX (%) | 6 (5.4) | 13 (11.6) | 0.149 |
| Steroid + MMF (%) | 50 (44.6) | 45 (40.2) | 0.589 |
Values for numeric data are presented as mean (standard deviation) or median [interquartile range]; for categorical data, as count (percent).
AI: activity NIH index; ANA: antinuclear antibodies; ATM: hydroxychloroquine; AZA: azathioprine; C3: complement factor 3; C4: complement factor 4; CI: chronicity NIH index; CNI: calcineurin inhibitor; CTX: cyclophosphamide; dsDNA: double-stranded DNA; eGFR: estimated glomerular filtration rate; IgA: Immunoglobulin A; IgG: Immunoglobulin G; IgM: Immunoglobulin M; ISN/RPS international society of nephrology/renal pathology society; LEF: leflunomide; MMF: mycophenolate mofetil; RAASi: renin-angiotensin-aldosterone system inhibitors; RBC: red blood cells; ssA: Sjögren's-syndrome-related antigen A; ssB: Sjögren's-syndrome-related antigen B; WBC: white blood cells.
Comparison of clinical parameters and drug between patients treated with or without belimumab at baseline
| Factor . | Standard therapy . | Belimumab . | P value . |
|---|---|---|---|
| Number of patients | 112 | 112 | |
| Laboratory examination | |||
| Serum creatinine, umol/L | 64.50 [56.38, 79.19] | 66.50 [55.00, 89.50] | 0.694 |
| eGFR | 107.64 [82.94, 120.57] | 108.58 [79.63, 120.32] | 0.700 |
| ≥90 (%) | 80 (71.4) | 76 (67.9) | 0.663 |
| ≥60 (%) | 94 (83.9) | 88 (78.6) | 0.392 |
| Serum albumin, g/L | 38.83 [34.77, 41.42] | 32.50 [28.70, 36.54] | <0.001 |
| C3, g/L | 0.93 (0.23) | 0.91 (0.25) | 0.590 |
| C4, g/L | 0.16 [0.13, 0.23] | 0.18 [0.11, 0.25] | 0.681 |
| IgA, g/L | 2.59 [1.96, 3.25] | 2.32 [1.75, 3.08] | 0.147 |
| IgG, g/L | 10.95 [8.17, 13.70] | 10.60 [7.68, 12.98] | 0.467 |
| IgM, g/L | 0.70 [0.51, 1.07] | 0.68 [0.45, 1.06] | 0.404 |
| Lupus anticoagulant | 1.58 [1.11, 2.40] | 1.08 [0.76, 1.68] | <0.001 |
| Proteinuria, g/24h | 0.78 [0.26, 2.45] | 1.17 [0.41, 2.58] | 0.059 |
| Urine WBC, WBC/ul | 12.00 [6.22, 33.11] | 13.25 [6.00, 42.25] | 0.906 |
| Urine RBC, RBC/ul | 14.75 [5.00, 52.50] | 12.00 [4.25, 53.75] | 0.443 |
| Positive ANA | 111 (99.1) | 107 (95.5) | 0.212 |
| Positive anti-dsDNA | 65 (58.0) | 58 (51.8) | 0.421 |
| Positive anti-Sm | 26 (23.2) | 31 (27.7) | 0.540 |
| Positive anti-ssA | 63 (56.2) | 62 (55.4) | 1.000 |
| Positive anti-ssB | 13 (11.6) | 18 (16.1) | 0.439 |
| Pathology | |||
| ISN/RPS class | |||
| III | 3 (10.3) | 5 (10.4) | 1 |
| IV | 15 (51.7) | 11 (22.9) | 0.013 |
| III/IV+V | 11 (37.9) | 25 (52.1) | 0.249 |
| V | 0 (0.0) | 7 (14.6) | 0.041 |
| Crescent (%) | 13.33 [0.00, 28.57] | 5.50 [0.00, 14.56] | 0.126 |
| AI | 7.00 [4.00, 9.00] | 5.00 [2.00, 10.00] | 0.150 |
| CI | 2.00 [1.00, 5.00] | 2.00 [1.00, 4.00] | 0.923 |
| Therapy | |||
| ATM (%) | 75 (67.0) | 85 (75.9) | 0.183 |
| AZA (%) | 1 (0.9) | 1 (0.9) | 1.000 |
| CNI (%) | 16 (14.3) | 54 (48.2) | <0.001 |
| CTX (%) | 6 (5.4) | 13 (11.6) | 0.149 |
| LEF (%) | 10 (8.9) | 8 (7.1) | 0.807 |
| MMF (%) | 54 (48.2) | 51 (45.5) | 0.789 |
| RAASi (%) | 43 (38.4) | 57 (50.9) | 0.080 |
| Steroid (%) | 107 (95.5) | 108 (96.4) | 1.000 |
| Dosage of steroid, mg/day | 15.00 [10.00, 20.00] | 15.00 [7.50, 25.62] | 0.726 |
| Major treatment regimen | |||
| Steroid only (%) | 32 (28.6) | 11 (9.8) | <0.001 |
| Steroid + CTX (%) | 6 (5.4) | 13 (11.6) | 0.149 |
| Steroid + MMF (%) | 50 (44.6) | 45 (40.2) | 0.589 |
| Factor . | Standard therapy . | Belimumab . | P value . |
|---|---|---|---|
| Number of patients | 112 | 112 | |
| Laboratory examination | |||
| Serum creatinine, umol/L | 64.50 [56.38, 79.19] | 66.50 [55.00, 89.50] | 0.694 |
| eGFR | 107.64 [82.94, 120.57] | 108.58 [79.63, 120.32] | 0.700 |
| ≥90 (%) | 80 (71.4) | 76 (67.9) | 0.663 |
| ≥60 (%) | 94 (83.9) | 88 (78.6) | 0.392 |
| Serum albumin, g/L | 38.83 [34.77, 41.42] | 32.50 [28.70, 36.54] | <0.001 |
| C3, g/L | 0.93 (0.23) | 0.91 (0.25) | 0.590 |
| C4, g/L | 0.16 [0.13, 0.23] | 0.18 [0.11, 0.25] | 0.681 |
| IgA, g/L | 2.59 [1.96, 3.25] | 2.32 [1.75, 3.08] | 0.147 |
| IgG, g/L | 10.95 [8.17, 13.70] | 10.60 [7.68, 12.98] | 0.467 |
| IgM, g/L | 0.70 [0.51, 1.07] | 0.68 [0.45, 1.06] | 0.404 |
| Lupus anticoagulant | 1.58 [1.11, 2.40] | 1.08 [0.76, 1.68] | <0.001 |
| Proteinuria, g/24h | 0.78 [0.26, 2.45] | 1.17 [0.41, 2.58] | 0.059 |
| Urine WBC, WBC/ul | 12.00 [6.22, 33.11] | 13.25 [6.00, 42.25] | 0.906 |
| Urine RBC, RBC/ul | 14.75 [5.00, 52.50] | 12.00 [4.25, 53.75] | 0.443 |
| Positive ANA | 111 (99.1) | 107 (95.5) | 0.212 |
| Positive anti-dsDNA | 65 (58.0) | 58 (51.8) | 0.421 |
| Positive anti-Sm | 26 (23.2) | 31 (27.7) | 0.540 |
| Positive anti-ssA | 63 (56.2) | 62 (55.4) | 1.000 |
| Positive anti-ssB | 13 (11.6) | 18 (16.1) | 0.439 |
| Pathology | |||
| ISN/RPS class | |||
| III | 3 (10.3) | 5 (10.4) | 1 |
| IV | 15 (51.7) | 11 (22.9) | 0.013 |
| III/IV+V | 11 (37.9) | 25 (52.1) | 0.249 |
| V | 0 (0.0) | 7 (14.6) | 0.041 |
| Crescent (%) | 13.33 [0.00, 28.57] | 5.50 [0.00, 14.56] | 0.126 |
| AI | 7.00 [4.00, 9.00] | 5.00 [2.00, 10.00] | 0.150 |
| CI | 2.00 [1.00, 5.00] | 2.00 [1.00, 4.00] | 0.923 |
| Therapy | |||
| ATM (%) | 75 (67.0) | 85 (75.9) | 0.183 |
| AZA (%) | 1 (0.9) | 1 (0.9) | 1.000 |
| CNI (%) | 16 (14.3) | 54 (48.2) | <0.001 |
| CTX (%) | 6 (5.4) | 13 (11.6) | 0.149 |
| LEF (%) | 10 (8.9) | 8 (7.1) | 0.807 |
| MMF (%) | 54 (48.2) | 51 (45.5) | 0.789 |
| RAASi (%) | 43 (38.4) | 57 (50.9) | 0.080 |
| Steroid (%) | 107 (95.5) | 108 (96.4) | 1.000 |
| Dosage of steroid, mg/day | 15.00 [10.00, 20.00] | 15.00 [7.50, 25.62] | 0.726 |
| Major treatment regimen | |||
| Steroid only (%) | 32 (28.6) | 11 (9.8) | <0.001 |
| Steroid + CTX (%) | 6 (5.4) | 13 (11.6) | 0.149 |
| Steroid + MMF (%) | 50 (44.6) | 45 (40.2) | 0.589 |
Values for numeric data are presented as mean (standard deviation) or median [interquartile range]; for categorical data, as count (percent).
AI: activity NIH index; ANA: antinuclear antibodies; ATM: hydroxychloroquine; AZA: azathioprine; C3: complement factor 3; C4: complement factor 4; CI: chronicity NIH index; CNI: calcineurin inhibitor; CTX: cyclophosphamide; dsDNA: double-stranded DNA; eGFR: estimated glomerular filtration rate; IgA: Immunoglobulin A; IgG: Immunoglobulin G; IgM: Immunoglobulin M; ISN/RPS international society of nephrology/renal pathology society; LEF: leflunomide; MMF: mycophenolate mofetil; RAASi: renin-angiotensin-aldosterone system inhibitors; RBC: red blood cells; ssA: Sjögren's-syndrome-related antigen A; ssB: Sjögren's-syndrome-related antigen B; WBC: white blood cells.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
